ImmunityBio, Inc.
NASDAQImmunityBio enters its May 8 earnings call navigating a securities fraud lawsuit, a wave of class-action filings over alleged drug promotion violations, and 14% of its float shorted — a combination that makes the upcoming print one of the more charged setups in small-cap biotech right now. The short side tells the dominant story here. Short interest at 14.3% of free float is not a…
IBRX SI utilization hits 94.66%, near 52-week peak of 100%, signaling tight borrow conditions for short sellers.
Snapshot as of 7 May 2026
ImmunityBio enters its May 8 earnings call navigating a securities fraud lawsuit, a wave of class-action filings over alleged drug promotion violations, and 14% of its float shorted — a combination that makes the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IBRX — free to start on ORTEX.
Sign up for free →Open IBRX on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live IBRX data →